Q-omics provides the consensus-scored CSF2RBP1 profile across patient tissues and cancer cell-line models. CSF2RBP1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CSF2RBP1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, CSF2RBP1 RNA expression shows 6,651 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, and STAD as cancer lineages where CSF2RBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSF2RBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSF2RBP1 survival associations across molecular data types. CSF2RBP1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSF2RBP1 RNA expression–survival associations across cancer types. High CSF2RBP1 expression shows unfavorable associations in SKCM, THYM, MESO, LUAD and OV, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for CSF2RBP1 RNA expression.
This table summarizes CSF2RBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSF2RBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSF2RBP1 shows lower tumor expression in HNSC and higher tumor expression in LUAD, READ and COAD. The HNSC box plot shows higher CSF2RBP1 RNA expression in normal versus tumor tissue (log2 FC = −0.422, t-test p = .002).
This table shows molecular features associated with CSF2RBP1 in patient tissues and cancer cell lines. In patient samples, CSF2RBP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
